Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Andrea B. Apolo(National Institutes of Health), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Colleen Watt(National Cancer Institute), Alan W.C. Tan(National Cancer Institute), Elad Sharon(National Cancer Institute), Min Yuen Teo(Memorial Sloan Kettering Cancer Center), Petros Grivas(Seattle Cancer Care Alliance), Jiaoti Huang(Space Science Institute), Rahul Atul Parikh(National Cancer Institute), Meagan Odegaard(National Cancer Institute), Daniel M. Geynisman(Fox Chase Cancer Center), Nicholas I. Simon(National Cancer Institute), Cecilia Mitchell(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Scot A. Niglio(National Cancer Institute), Mehmet Asım Bilen(Emory Healthcare), Daniel P. Petrylak(Yale University), Guru Sonpavde(AdventHealth Orlando), Susan Halabi(Duke Medical Center), Yujia Wen(National Cancer Institute), Bradley A. McGregor(Harvard University), Joseph W. Kim(National Cancer Institute), Michael Woods(University of Cambridge), Stephanie Berg(Loyola University Medical Center), Randy F. Sweis(University of Illinois Chicago), Karla V. Ballman(Mayo Clinic in Arizona), Parminder Singh(WinnMed), Suzanne Cole(National Cancer Institute), Abhishek Tripathi(ITM University), Jeannie Hoffman-Censits(Johns Hopkins University), William Y. Kim(University of North Carolina at Chapel Hill), Gurkamal Chatta(Roswell Park Comprehensive Cancer Center), Howard Streicher(National Cancer Institute), Zachery R. Reichert(National Cancer Institute), Lisa Ley(National Cancer Institute), Sandy Srinivas(Stanford University), Helen Moon(National Cancer Institute), Michael J. Morris(Dana-Farber Cancer Institute), Olwen Hahn(National Cancer Institute), Gabriela Perez Burbano(National Cancer Institute)
Cited by 145
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k